Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery
Status:
Completed
Trial end date:
2019-08-20
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the safety and efficiency of Remodulin®（Treprostinil
Injection）to reduce the pulmonary arterial pressure and prevent pulmonary hypertension (PH)
after Fontan operation with univentricular physiology.